Articles from Anova Enterprises, Inc.

Anova Enterprises, Inc. (Anova), a technology-enabled CRO dedicated to improving the conduct of clinical trials, today announced the completion of enrollment of 550+ patients at 50+ sites for a single study in just six months, using it’s proprietary AnovaOS™ Platform. The program provided cancer doctors and patients with a promising treatment that was otherwise unavailable. The sponsor was provided with safety and efficacy data to support its drug development efforts.

Anova Enterprises, Inc. (Anova), a technology-enabled CRO dedicated to improving the conduct of clinical trials, has announced the launch of a global clinical registry to accelerate the development of promising new treatments. The 21 CFR Part 11 compliant AnovaOS® global clinical registry provides a rich source of real-world evidence about research sites and patients, administrative efficiency in the conduct of research, a tool for post-market surveillance, and information to support data-driven study design, with the effect of faster go-to-market timelines for sponsors.

Anova Enterprises, Inc. (Anova), a technology-enabled CRO dedicated to accelerating promising treatments, has announced enrollment of the first two patients in the highly anticipated study of DB107 for the treatment of brain tumors. The Phase 1/2a clinical trial is a multicenter, open-label study designed to confirm whether treatment DB107, when added to standard-of-care (SOC), provides clinical benefit to patients with newly diagnosed high-grade gliomas (HGG) when compared to historical performance.

Anova Enterprises, Inc. (Anova), a leading technology-enabled contract research organization (CRO) dedicated to accelerating clinical development, proudly announces the appointment of Fred Ma, MD, PhD, Adam Callahan, MBA, and Rhonda Rosen, MBA, CPA., to key executive roles. The expansion of Anova’s leadership team reflects the companies significant growth, and adds decades of transformative leadership in the pharmaceutical, biotechnology, and medical device industries, to Anova's leadership team. The expanded Executive leadership team remains committed to transforming the delivery of complex clinical trials from one where sites are activated in the hope they can identify/enroll patients to one where the right trial is available to patients where they receive care.

Anova Enterprises, Inc. (Anova), a technology enabled CRO dedicated to accelerating promising treatments, has collaborated with University of California at San Francisco (UCSF), University of California at San Diego (UCSD), the University of Southern California (USC) and Denovo Biopharma to manage a newly awarded $11.8M California Institute for Regenerative Medicine (CIRM) grant to support the development of DB107 in patients with newly diagnosed high-grade glioma.

Anova Enterprises, Inc. (Anova), an organization dedicated to accelerating promising treatments to market with its transformative AnovaOS™ technology platform, and the industry’s first collaborative ‘learning system’, today announced a partnership with Dizal Pharmaceuticals (Dizal) to accelerate the development of DZD9008 for patients with EGFR Exon20ins mutant NSCLC.

Anova Enterprises, Inc. (Anova), an organization dedicated to accelerating the development of promising treatments to market announced the FDA authorization of a Phase II clinical trial to re-assess a targeted treatment in light of newly discovered pharmacogenomic predictor data in patients with newly diagnosed high-grade glioma (HGG).

Anova Enterprises, Inc. (Anova), an organization dedicated to accelerating promising treatments to market with its transformative AnovaOS™ technology platform, and the industry’s first collaborative ‘learning system’, today announced a partnership with the Mary Crowley Cancer Research (Mary Crowley) to establish and support a technology enabled approach to extend early Phase clinical trials to cancer patients in the Southern and Southwestern United States.

Anova Enterprises, Inc. (Anova), an organization dedicated to accelerating promising treatments to market with its transformative AnovaOS™ technology platform, has launched a global patient registry study for 100,000 patients with complex and/or rare disease.

Anova Enterprises, Inc. (Anova), an organization dedicated to accelerating promising treatments to market with its transformative AnovaOS™ technology platform, continues to see the benefits of improved access to investigational treatment for patients with serious, complex and rare disease.